Nishikawa, Kazuhiro http://orcid.org/0000-0003-1213-2732
Koizumi, Wasaburo
Tsuburaya, Akira
Yamanaka, Takeharu
Morita, Satoshi
Fujitani, Kazumasa
Akamaru, Yusuke
Shimada, Ken
Hosaka, Hisashi
Nakayama, Norisuke
Tsujinaka, Toshimasa
Sakamoto, Junichi
Article History
Received: 16 April 2019
Accepted: 6 July 2019
First Online: 15 July 2019
Compliance with ethical standards
:
: Kazuhiro Nishikawa has received honoraria from Chugai, Taiho, Yakult, Eli Lilly, Tsumura, and EA Pharma, and research funding from Yakult and Taiho, outside the submitted work. Takeharu Yamanaka reports personal fees from Takeda, Taiho, Chugai and Boehringer, outside the submitted work. Satoshi Morita reports personal fees from Daiichi-Sankyo, outside the submitted work. Toshimasa Tsujinaka reports personal fees from Lilly, outside the submitted work. All remaining authors have declared no conflict of interest.
: This trial was conducted in compliance with the ethical principles of the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies of the Japanese Ministry of Health, Labour and Welfare. This trial was approved by the institutional review boards or ethics committees at all participating centers. This trial was registered with Clinical Trials.gov (UMIN 000025367).
Free to read: This content has been made available to all.